OncoMed Pharmaceuticals Company Profile (NASDAQ:OMED)

Analyst Ratings

Consensus Ratings for OncoMed Pharmaceuticals (NASDAQ:OMED) (?)
Ratings Breakdown: 2 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.71)
Consensus Price Target: $20.33 (67.63% upside)

Analysts' Ratings History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Show:
DateFirmActionRatingPrice TargetActions
7/14/2016Cantor FitzgeraldReiterated RatingBuy$16.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016MizuhoLower Price TargetNeutral$45.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/22/2016Jefferies GroupReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/5/2016Leerink SwannBoost Price TargetMarket Perform$11.00 -> $13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$21.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/3/2015Wells Fargo & Co.Initiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Piper Jaffray Cos.Set Price TargetBuy$43.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for OncoMed Pharmaceuticals (NASDAQ:OMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/5/2016Q1($0.73)($0.90)$8.28 million$6.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q4$0.41$1.50$44.55 million$6.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.80)($0.81)$5.84 million$4.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.49)($0.72)$13.78 million$4.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.35)($0.49)$15.35 million$9.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.27)($0.50)$11.92 million$8.51 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014($0.30)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.03)($0.53)$21.28 million$6.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.13)($0.47)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/18/2014Q4 13$0.15($0.15)$20.37 million$19.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3$0.12($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
9/3/2013Q2 2013($0.02)($0.83)$8.31 million$2.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for OncoMed Pharmaceuticals (NASDAQ:OMED)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.94)$1.15($0.21)
Q2 20161($0.87)($0.87)($0.87)
Q3 20163($0.75)($0.58)($0.66)
Q4 20161($0.74)($0.74)($0.74)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for OncoMed Pharmaceuticals (NASDAQ:OMED)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for OncoMed Pharmaceuticals (NASDAQ:OMED)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/11/2016Jakob DupontSVPSell2,500$20.01$50,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016Alicia J. HagerVPSell1,623$22.28$36,160.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016John A. LewickiEVPSell2,162$22.28$48,169.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/6/2016Paul J. HastingsCEOSell2,412$22.28$53,739.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Alicia J. HagerVPSell1,800$23.14$41,652.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/27/2015Alicia J. HagerVPSell5,400$21.00$113,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Austin GurneyInsiderSell14,000$20.00$280,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/26/2015Jakob DupontSVPSell5,000$20.00$100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015Jack W. LasersohnDirectorBuy11,210$16.01$179,472.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2015Jack W. LasersohnDirectorBuy3,140$14.15$44,431.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015Jack W. LasersohnDirectorBuy10,000$14.74$147,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/10/2015Jakob DupontSVPSell2,500$20.13$50,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015Jakob DupontSVPSell2,500$21.22$53,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015Alicia J HagerVPSell1,800$22.67$40,806.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/22/2015Timothy HoeySVPSell5,000$26.07$130,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2015John A LewickiEVPSell17,000$25.07$426,190.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015John A LewickiEVPSell8,500$24.92$211,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015Alicia J HagerVPSell1,800$23.07$41,526.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/18/2015Austin GurneyInsiderSell4,000$22.48$89,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Alicia J HagerVPSell1,800$25.65$46,170.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/27/2015Timothy HoeySVPSell6,887$25.65$176,651.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/17/2015Austin GurneyInsiderSell4,000$25.51$102,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/10/2015Jakob DupontSVPSell1,500$26.51$39,765.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/2/2015John A LewickiEVPSell17,000$25.28$429,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Sunil PatelInsiderSell18,000$27.76$499,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Austin GurneyInsiderSell4,000$27.37$109,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2015Timothy HoeySVPSell7,500$22.83$171,225.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015John A LewickiEVPSell4,000$22.49$89,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/20/2015Austin GurneyInsiderSell4,000$22.87$91,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Jakob DupontSVPSell1,500$25.89$38,835.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/5/2015Jakob DupontSVPSell7,500$23.00$172,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015John A LewickiEVPSell4,000$22.10$88,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/31/2014Denise Pollard-KnightDirectorSell3,799$21.66$82,286.34View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/30/2014Denise Pollard-KnightDirectorSell17,607$21.63$380,839.41View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/18/2014Jonathan D RootDirectorSell13,052$21.05$274,744.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014Denise Pollard-KnightDirectorSell32,940$21.78$717,433.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014Denise Pollard-KnightDirectorSell23,273$21.78$506,885.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014Denise Pollard-KnightDirectorSell1,727$21.68$37,441.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2014Denise Pollard-KnightDirectorSell25,000$21.60$540,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014John A LewickiEVPSell4,000$21.19$84,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2014Timothy HoeySVPSell2,500$19.51$48,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2014Paul J HastingsCEOSell16,769$21.99$368,750.31View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/2/2014John A LewickiEVPSell5,809$20.00$116,180.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/4/2014Jack W LasersohnDirectorBuy3,170$18.35$58,169.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2014Jack W LasersohnDirectorBuy3,000$18.40$55,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014John A LewickiEVPSell2,191$20.01$43,841.91View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2014Deepika PakianathanDirectorBuy80,203$18.98$1,522,252.94View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/15/2014Jack W LasersohnDirectorBuy1,045$17.00$17,765.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/5/2014Timothy HoeySVPSell2,500$21.66$54,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2014John A LewickiEVPSell4,000$20.98$83,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2014Paul J HastingsCEOSell16,770$22.11$370,784.70View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2014Austin GurneyInsiderSell4,000$20.46$81,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014John A LewickiEVPSell4,000$23.86$95,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2014Denise Pollard-KnightDirectorSell11,485$23.59$270,931.15View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014Denise Pollard-KnightDirectorSell3,252$23.56$76,617.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2014Denise Pollard-KnightDirectorSell64,561$24.08$1,554,628.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/17/2014Austin GurneyInsiderSell4,000$24.99$99,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/16/2014John A LewickiEVPSell4,000$24.59$98,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2014Presidio Management Group ViiiMajor ShareholderSell13,052$24.57$320,687.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Presidio Management Group Viiimajor shareholderSell46,327$21.99$1,018,730.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2013Denise Pollard-KnightDirectorBuy58,824$17.00$1,000,008.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2013Presidio Management Group ViiiMajor ShareholderBuy158,823$17.00$2,699,991.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for OncoMed Pharmaceuticals (NASDAQ:OMED)
DateHeadline
07/28/16 08:49 AMNon Small Cell Lung Cancer Pipeline Development Market Report 2016
07/23/16 09:33 AMOncomed Pharmaceuticals Incorporated (NASDAQ:OMED) Shorted Shares Increased 8.48% After Market Selling - Press Telegraph
07/23/16 09:33 AMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/23/16 09:33 AMOncoMed Pharmaceuticals Inc (NASDAQ:OMED) Stock Technicals Hit Extreme Weakness - CML News
07/23/16 09:33 AMShares Stumbling of Late: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - TGP
07/20/16 06:24 PMEquity Roundup: Stock Performance Focus on OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Press Telegraph
07/20/16 06:24 PMIs $29 Price Target Attainable For OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)? - Investor Newswire
07/19/16 07:00 AMEarnings Focus and Crowd Sourced Sentiment Review for OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - TGP
07/17/16 09:51 AMShares Moving Down on the Week: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Engelwood Daily
07/17/16 09:51 AMShares Experiencing a Downtrend: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - TGP
07/17/16 09:51 AMHow Many Oncomed Pharmaceuticals Inc (NASDAQ:OMED)'s Analysts Are Bullish? - Press Telegraph
07/15/16 10:37 AMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/15/16 10:37 AMOncomed Pharmaceuticals Inc on Focus After Crashing In Today's Session - Consumer Eagle
07/14/16 09:14 AMStrong Sell Calls For OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) At 0 - Investor Newswire
07/12/16 05:55 PMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/12/16 05:55 PMOncomed Pharmaceuticals Incorporated (NASDAQ:OMED) Shorted Shares Increased 9.21% After Market Selling - Press Telegraph
07/12/16 05:55 PMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Broker Price Targets For The Coming Week - Fiscal Standard
07/12/16 05:55 PMOncomed Pharmaceuticals Inc (NASDAQ:OMED): Stock Institutional Investors Are Bullish About - Consumer Eagle
07/12/16 05:55 PMOncoMed Pharmaceuticals Inc Realized Volatility Hits Extreme Level - CML News
07/11/16 05:38 PMGlobal Solid Tumors Drugs Market to Grow at a CAGR of 8.6% During the Period 2016 - 2020; Finds New Report
07/10/16 09:46 AMHow Many Oncomed Pharmaceuticals Inc (NASDAQ:OMED)'s Analysts Are Bearish? - Press Telegraph
07/08/16 05:40 PMWilliam D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board
07/08/16 08:36 AMTrending Stocks: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), Frequency Electronics Inc. (NASDAQ:FEIM ... - KC Register
07/07/16 05:41 PMCan OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Improve on the Earnings Front? - Engelwood Daily
07/07/16 04:31 PMOncoMed Management to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - July 7, 2016 REDWOOD CITY, Calif., July 07, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing ...
07/07/16 08:32 AMStock Tracking Down This Month; Investor Alert on OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Engelwood Daily
07/07/16 08:32 AMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Expected to Reach Highs Of $29 - Investor Newswire
07/05/16 11:21 AMOncoMed Pharmaceuticals, Inc. – Value Analysis (NASDAQ:OMED) : July 5, 2016 -
07/04/16 07:16 AMOncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : OMED-US : July 4, 2016 -
07/01/16 08:26 AMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Earnings Glance and Target Price Review - Engelwood Daily
06/30/16 08:29 AMNew Broker Ratings For OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - FTSE News
06/29/16 08:29 AMOncoMed Pharmaceuticals Inc. (OMED) Jumps 6.29% on June 28 - Equities.com
06/27/16 09:50 AMNext Weeks Broker Price Targets For OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - Fiscal Standard
06/26/16 10:09 AMONCOMED PHARMACEUTICALS INC : Submission of Matters to a Vote of Security Holders (form 8-K)
06/25/16 09:20 AMOncomed Pharmaceuticals Inc's Stock Is Sell After Today's Gap Down - Engelwood Daily
06/24/16 03:40 PMONCOMED PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/23/16 06:09 PMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Current Analyst Ratings - Fiscal Standard
06/23/16 06:09 PMStrong Buy Calls Count For OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) At 6 - Investor Newswire
06/21/16 07:23 AMOncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : OMED-US : June 21, 2016 -
06/20/16 05:28 PMThe Pros And Cons Of Pfizer Separating GEP
06/10/16 07:26 AMOncoMed Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : OMED-US : June 10, 2016 -
06/08/16 06:02 PMOncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Decreased -8.14%: Facebook Inc (NASDAQ:FB), AT&T, Inc. (NYSE ... - KC Register
06/08/16 06:02 PMONCOMED PHARMACEUTICALS INC. (NASDAQ:OMED) Financial Condition Compared to S&P 500 - CML News
06/07/16 08:21 AMSprint Corporation (NYSE:S) Went Up 1.59%: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), eFuture Holding Inc ... - KC Register
06/06/16 05:34 PMOncoMed Pharmaceuticals (NASDAQ:OMED) Tumbled -6.25%: Apple Inc. (NASDAQ:AAPL), Telefonaktiebolaget LM ... - KC Register
06/06/16 05:34 PMOncoMed Pharma (OMED) Presents Data on Four Clinical-Stage Programs at ASCO 2016 - StreetInsider.com
06/06/16 07:18 AMOncoMed Management to Present at Two Upcoming Investment Conferences - [at noodls] - June 6, 2016 REDWOOD CITY, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing ...
06/05/16 05:38 PMOncoMed Pharmaceuticals Inc.: OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and ... - The Wall Street Transcript
06/05/16 08:08 AMOncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting - [at noodls] - June 5, 2016 First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab Updated Data for Demcizumab and Tarextumab Also Presented CHICAGO and REDWOOD CITY, Calif., June 05, 2016 ...
06/04/16 08:30 AMStock Review and Earnings Check on OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) - HNN

Social

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals logoOncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical development-stage biopharmaceutical company. The Company focuses on discovering and developing anti-cancer stem cell (CSC) and immuno-oncology therapeutics. The Company's product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Anti-DLL4/VEGF Bispecific (OMP-305B83), Anti-RSPO3 (OMP-131R10) and GITRL-Fc. The Company's Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4), in the Notch signaling pathway. Tarextumab is an antibody that binds to both the Notch2 and Notch3 receptors. Ipafricept is the Company's Wnt pathway modulator. GITRL-Fc is a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor related protein.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: OMED
  • CUSIP:
Key Metrics:
  • Previous Close: $12.22
  • 50 Day Moving Average: $12.38
  • 200 Day Moving Average: $11.62
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $367.51M
  • Beta: 2.93
  • Current Year EPS Consensus Estimate: $-3.1 EPS
  • Next Year EPS Consensus Estimate: $-1.59 EPS
Additional Links:
OncoMed Pharmaceuticals (NASDAQ:OMED) Chart for Saturday, July, 30, 2016